계명대학교 의학도서관 Repository

Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia

Metadata Downloads
Author(s)
Jong-Seon ParkYoung-Jo KimJi-Yong ChoiYoon-Nyun KimTeck-Jong HongDong-Soo KimKi-Young KimMyung-Ho JeongJei-Keon ChaeSeok-Kyu OhIn-Whan Seong
Keimyung Author(s)
Kim, Yoon Nyun
Department
Dept. of Internal Medicine (내과학)
Journal Title
Korean Journal of Internal Medicine
Issued Date
2010
Volume
25
Issue
1
Keyword
Metabolic syndrome XHypercholesterolemiaRosuvastatinAtorvastatin
Abstract
Background/Aims

This multicenter, open-labeled, randomized trial was performed to compare the effects of rosuvastatin 10 mg and atorvastatin 10 mg on lipid and glycemic control in Korean patients with nondiabetic metabolic syndrome.


Methods

In total, 351 patients who met the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for metabolic syndrome with low-density lipoprotein cholesterol (LDL-C) levels ≥ 130 mg/dL were randomized to receive either rosuvastatin 10 mg (n = 173) or atorvastatin 10 mg (n = 178) for over 6 weeks.


Results

After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group. Overall, the percentage of patients attaining the NCEP ATP III goal was higher with rosuvastatin as compared to atorvastatin (87.64 vs. 69.88%, p < 0.001). Changes in glucose and insulin levels, and homeostasis model assessment of insulin resistance index were not significantly different between the two groups. The safety and tolerability of the two agents were similar.


Conclusions

Rosuvastatin 10 mg was more effective than atorvastatin 10 mg in achieving NCEP ATP III LDL-C goals in patients with nondiabetic metabolic syndrome, especially in those with lower NCEP ATP III target level goals.

Keywords: Metabolic syndrome X, Hypercholesterolemia, Rosuvastatin, Atorvastatin
Keimyung Author(s)(Kor)
김윤년
Publisher
School of Medicine
Citation
Jong-Seon Park et al. (2010). Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia. Korean Journal of Internal Medicine, 25(1), 27–35. doi: 10.3904/kjim.2010.25.1.27
Type
Article
ISSN
1226-3303
DOI
10.3904/kjim.2010.25.1.27
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/34568
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.